OncoPharm

There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape.

Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.

We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target.

Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30).

Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cholangiocarcninoma.

RET fusions: https://doi.org/10.1016/j.ctrv.2019.101911

PAOLA-1: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361

IMbrave150: https://www.nejm.org/doi/full/10.1056/NEJMoa1915745

Olanzapine: https://jamanetwork.com/journals/jamaoncology/article-abstract/2765323

Ivosidenib in cholangiocarcinoma: https://doi.org/10.1016/S1470-2045(20)30157-1

First, we discuss the FDA approval of daratumumab hyaluronidase for subcutaneous administration and compare its administration to SC administration of rituximab hyaluronidase and trastuzumab hyaluronidase.

We end by discussing the 1st FDA-approved drug for MET exon 14 skipping mutations, capmatinib. We also discuss how a receptor tyrosine kinase could skip.

Topics of discussion:

Q 6 week pembrolizumab dosing schedule FDA approved

Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28)

The monarcHER study of abemaciclib in HER+ MBC (12:20)

The GRIFFIN study of Dara+VRD in myeloma (17:00)

Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.

Our 1st Journal Club.

1. Read this: https://www.futuremedicine.com/doi/10.2217/fon-2018-0787

2. Ask how, or if, this would change practice.

3. Listen.

First, we run through 4 recent FDA-approved expanded indications for HCC, small cell lung cancer, MDS-related anemia, and BRAF-v600e-mutated colorectal cancer.

Then, we review the evidence that warranted bevacizumab's FDA-approval for metastatic breast cancer way back in 2008 (E2100) and its subsequent labeled indication removal by the FDA (Avado & Ribbon-1).

Why talk about old news? Perhaps there's a lesson here as we consider using untested drugs...

E2100: https://www.nejm.org/doi/full/10.1056/nejmoa072113

Avado: https://www.ncbi.nlm.nih.gov/pubmed/20498403

Ribbon-1: https://www.ncbi.nlm.nih.gov/pubmed/21383283

Reviewing the lasted DOAC study in treating cancer-associated VTE: Caravaggio. We compare it the other major DOAC studies in this patient population. Caravaggio: https://www.nejm.org/doi/full/10.1056/NEJMoa1915103

Also, announcing our first journal club! This will be our 4/16 Pod. It is especially for an oncology APPE students missing out on an oncology experience, but all are welcome to participate. Journal Club link: https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0787

The Foundations of OncoPharm series returns with a unique chemotherapy drug: bleomycin.

Also, Covid Thoughs (14:00).

Recent updated survival analyses for CLEOPATRA and Keynote-189 (6:45) require some historical context to truly see their impact. Finally, #AskOncoPharm returns (15:05) with a listener question about infusion rates when restarting daratumumab.